Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
Chỉ hiển thị Multimedia

Aficamten retains upper hand over metoprolol for oHCM in subanalysis
14 Sep 2026
bởiAudrey Abella
Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.
14 Sep 2026

Uromodulin levels do not predict hypertension
11 Sep 2026
bởiStephen Padilla
Uromodulin, as a protein and genetic biomarker, is not a reliable predictor of hypertension or hypertension-related outcomes, reveals a study. However, it may have potential use in the prediction of other cardiovascular outcomes.
11 Sep 2026






